A Phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with MET-overexpressing NSCLC
REGN5093-M114
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: A Phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with MET-overexpressing NSCLC ### Output: REGN5093-M114